📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Endo

1.1 - Company Overview

Endo Logo

Endo

Headquarter: Ireland
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of branded and generic pharmaceuticals for patient care, offering affordable, high-quality generics and treatments for unmet pelvic health needs; supplies products tailored to Canadian and emerging markets, and engages in public policy advocacy to enhance patient access, alongside a UK tax strategy focused on compliance and responsible planning.

Products and services

  • Affordable, High-Quality Generic Pharmaceuticals: Endo produces generic pharmaceuticals that aim to be both affordable and high quality for patient care, delivering generic-class products that expand access to necessary treatments
  • High-Value Branded Pharmaceutical Products: Endo offers branded pharmaceutical products addressing various medical needs, supplying branded-class medications developed for patient care with an emphasis on value and addressing defined needs
  • Treatments for Unmet Pelvic Health Needs: Endo delivers specific pelvic-health-focused treatments targeting today’s unmet needs, supplying products intended to address current pelvic health gaps within patient care

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Endo

Pharmion Logo

Pharmion

HQ: United States Website
  • Description: Provider of products for the treatment of hematology and oncology patients, focused on acquisition, development, and commercialization. Global biotech partnering with scientific and clinical advisors to identify and develop products for hematology and oncology markets.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Pharmion company profile →
Herantis Pharma Logo

Herantis Pharma

HQ: Finland Website
  • Description: Provider of pharmaceutical therapies targeting unmet clinical needs, including HER-096, a small synthetic peptidomimetic based on the CDNF protein's active site for treating Parkinson’s disease, designed for subcutaneous administration and demonstrating good safety, tolerability, and efficient blood-brain barrier penetration in Phase 1a clinical trials.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Herantis Pharma company profile →
Sirona Biochem Logo

Sirona Biochem

HQ: Canada Website
  • Description: Provider of biotechnology solutions including diabetes therapeutics, cosmetic skin depigmenting and anti-aging agents, biological ingredients and cancer vaccine antigens. Offers compounds such as TFC-1067, LIP-01 and SGLT2 inhibitors, enabled by GlycoMim technology and fluorination chemistry to stabilize carbohydrate-based molecules and enhance pharmaceutical and cosmetic properties.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sirona Biochem company profile →
Neutrolis Logo

Neutrolis

HQ: United States Website
  • Description: Provider of candidate-stage, first-in-class anti-NET therapies, including the exDNASETM platform to create molecules that disassemble Neutrophil Extracellular Traps; NTR-L303 to resolve hyperinflammation and disrupt NET-immune complexes; NEU-101 for surface inflammation; and NET biomarkers to identify, treat, and monitor responsive patients.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Neutrolis company profile →
Vicore Pharma Logo

Vicore Pharma

HQ: Sweden Website
  • Description: Provider of pharmaceuticals for severe lung disorders, developing drugs acting through the angiotensin II type 2 (AT2) receptor, including buloxibutid (C21), an orally available ATRAG in phase 2a for idiopathic pulmonary fibrosis (IPF) with orphan drug designation in the EU, and Almee, a digital therapeutic based on cognitive behavioral therapy to address the psychological impact of pulmonary fibrosis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Vicore Pharma company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Endo

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Endo

2.2 - Growth funds investing in similar companies to Endo

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Endo

4.2 - Public trading comparable groups for Endo

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Endo

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Endo

What does Endo do?

Endo is a provider of branded and generic pharmaceuticals for patient care, offering affordable, high-quality generics and treatments for unmet pelvic health needs; supplies products tailored to Canadian and emerging markets, and engages in public policy advocacy to enhance patient access, alongside a UK tax strategy focused on compliance and responsible planning.

Who are Endo's competitors?

Endo's competitors and similar companies include Pharmion, Herantis Pharma, Sirona Biochem, Neutrolis, and Vicore Pharma.

Where is Endo headquartered?

Endo is headquartered in Ireland.

How many employees does Endo have?

Endo has 1,000 employees 🔒.

When was Endo founded?

Endo was founded in 2010 🔒.

What sector and industry vertical is Endo in?

Endo is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Endo

Who are the top strategic acquirers in Endo's sector and industry

Top strategic M&A buyers and acquirers in Endo's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Endo?

Top strategic M&A buyers groups and sectors for Endo include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Endo's sector and industry vertical

Which are the top PE firms investing in Endo's sector and industry vertical?

Top PE firms investing in Endo's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Endo's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Endo's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Endo's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Endo include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Endo's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Endo?

The key public trading comparables and valuation benchmarks for Endo include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Endo for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Endo with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Endo's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Endo with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Endo's' sector and industry vertical?

Access recent funding rounds and capital raises in Endo's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Endo